Compugen Ltd - רווח נקי למניה בארבעת הרבעונים האחרונים CGEN
Compugen Ltd. (CGEN) maintains a steady stream of funding through molecule licensing, powered by its proprietary oncology target discovery system. The company's price chart reflects EPS TTM dynamics, which currently stand at 228.80. The financial model relies on strategic alliances with pharma behemoths rather than mergers. High potential for AI-driven breakthroughs in cancer therapy attracts leading biologists and immunologists to the team.
CGEN (Compugen Limited): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The speculative potential of Compugen Ltd. (CGEN) is supported by its AI platform and payments from pharma behemoths, which minimize R&D risks. Analyzing the annual EPS TTM chart, an investor assesses the rate of change in net income per share over the last twelve months. This metric reveals the balance between cost inflation and real growth in business profitability. A stable trend confirms capital resilience and the effectiveness of the current intellectual property monetization strategy.
